Health Press Release – Weekly Newsletter for January 10-17, 2011
Monday, January 17, 2011
Takeda San Francisco and Pieris Sign Anticalin(R) Therapeutic Collaboration
SAN FRANCISCO and FREISING, Germany, January 10, 2011 – Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery
partnership agreement under which Pieris will apply its Anticalin(R) scaffold
technology to deliver protein therapeutic candidates to Takeda, both
companies announced today. The deal initially will focus on first-in-class
drug discovery efforts around a predetermined Takeda target. [..] Read the original article: here.
Over 700 Elsevier Science & Technology Books Now Available in Research4Life
Leading Publisher Offers Electronic Books to UN Program Providing Research Access to the Developing World
BURLINGTON, Massachusetts, January 10, 2011 – Burlington, MA, 10 January 2011 – Elsevier, a world-leading publisher of
scientific, technical and medical information products and services, today
announced that 780 of its science and technology electronic books will be
added to Research4Life (www.research4life.org/). Elsevier … Read : Over 700 Elsevier Science & Technology Books Now Available in Research4Life.
Interim Results From Mesoblast’s Phase 2 Heart Failure Trial Shows ‘Off-the-Shelf’ Proprietary Adult Stem Cell Product Revascor(TM) Reduces Cardiac Events, Mortality, and Hospitalization
FRAZER, Pennsylvania and MELBOURNE, Australia, January 10, 2011 – Cephalon, Inc. (Nasdaq: CEPH) and Mesoblast Limited (ASX: MSB; OTC ADR:
MBLTY) today announced positive interim results from Mesoblast's ongoing
multi-center Phase 2 trial of its "off-the-shelf" proprietary adult stem cell
product Revascor(TM) for patients with congestive heart failure. Patients who
received a single injection of Revascor(TM) into damaged … Read more »».
Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring
CARLSBAD, California, January 10, 2011 – Excaliard Pharmaceuticals, Inc., today announced results from three Phase
2 clinical trials of EXC 001 in skin scarring. EXC 001 is an antisense
oligonucleotide designed to interrupt the process of fibrosis by inhibiting
expression of connective tissue growth factor (CTGF). The three studies
demonstrated EXC 001's efficacy in elective revision surgery of …. Original article on Gaea Times at : Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring.
Avexxin Closes Financing Round
Financing Will be Used to Develop Avexxin's Lead Compound Against Psoriasis Through Clinical Phase I/IIa
TRONDHEIM, Norway, January 10, 2011 – Avexxin AS, a Norwegian pharma company focusing on the
development of novel small molecule therapeutics for patients suffering from
chronic inflammatory conditions, announces the closure of a financing round
enabling the company to take its lead compound …. Original source : Avexxin Closes Financing Round.
Abbott Receives CE Mark Approval for World’s First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Abbott's Newest Innovation Can Treat a Patient's Blocked Heart Vessel and Then Dissolve, Leaving the Patient's Vessel Free of a Permanent Metallic Implant
ABBOTT PARK, Illinois, January 10, 2011 – Abbott (NYSE: ABT) announced today that it has received CE Mark approval
for the world's first drug eluting bioresorbable vascular scaffold (BVS) for
the treatment of coronary … Read : Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease.
Health Robotics Expands i.v.STATION(R) Footprint in North America With Children’s Hospital of Los Angeles
BOZEN, SUD-TIROL, Italy, January 10, 2011 – Health Robotics today announced its first 2011 contract for the
installation of 2 i.v.STATION robots at Children's Hospital of Los Angeles,
marking the third California hospital, after Cottage Health System and
Memorial Care, to purchase 2 i.v.STATIONs each. The installation of the 2
i.v.STATIONs is scheduled to occur during 1Q2011 initially …. Read the original article : Health Robotics Expands i.v.STATION(R) Footprint in North America With Children's Hospital of Los Angeles.
New Treatment to Improve Vision Loss for People With Diabetes
For UK Media Only
FRIMLEY, England, January 11, 2011 – Novartis Pharmaceuticals UK Ltd today announced that
Lucentis(R) (ranibizumab) is being launched in the UK for the treatment of
visual impairment due to diabetes, specifically diabetic macular oedema
(DMO). This offers fresh hope for people with this serious and common
complication of diabetes. Ranibizumab is the first licensed therapy …. Original source : New Treatment to Improve Vision Loss for People With Diabetes.
MDMA Announces Business Alliance With WMDO to Provide Online MedTech Industry Training
MDMA Members to Receive Access to WMDO's Online Medical Device Curriculum
WASHINGTON D.C. and MINNEAPOLIS, January 11, 2011 – MDMA (Medical Device Manufacturers Association), the leading national
trade association for innovative and entrepreneurial medical technology
companies and WMDO (World Medical Device Organization), the leading global
provider of innovative online training for medical device professionals,
announced today a business alliance … Read more >>.
Invitation: 12th St. Gallen International Breast Cancer Conference, March 16-19, 2011
ST. GALLEN, Switzerland, January 11, 2011 – This bi-annual conference will highlight meaningful advances
concerning treatment of Early Breast Cancer (EBC). The conference will build
up on earlier diagnostic and therapeutic recommendations and thereafter
provide written guidelines for the international community. Breast cancer
specialists from all over the world are awaiting these new guidelines.
EyeSense Attracts QIAGEN as Strategic Investor
Strategic Partnership to Develop and Commercialize a Novel Ophthalmic Self-Diagnostic System for Blood Glucose Monitoring by Diabetes Patients
BASEL, Switzerland, January 11, 2011 – EyeSense AG, a leading developer of novel ophthalmic self-diagnostic
systems for glucose monitoring of diabetes patients, today announced that it
has entered into a strategic partnership with QIAGEN (NASDAQ: QGEN;
Frankfurt, Prime Standard: QIA). …. Read the original article : EyeSense Attracts QIAGEN as Strategic Investor.
Financial Fear of the Dentist Worse Than the Drill
LONDON, January 12, 2011 – It used to be a fear of the dentist that kept us away from the dental
chair but today it is more than twice as likely to be the cost of dental care
that's holding us back, according to research from Tesco Dental Insurance
(www.tescofinance.com/personal/finance/insurance/dentalins/index.jsp).
Over a third of …. Read the original article : Financial Fear of the Dentist Worse Than the Drill.
Revolutionary Treatment Tops ME/ CFS Poll
LONDON, January 12, 2011 – A revolutionary self training course has emerged top in a survey
conducted by the Sussex and Kent ME/ CFS Society.
In a poll of 457 members, tracking their experiences over two years, 44
per cent of the society's members found the Lightning Process "very helpful"
and 36 per cent … Read more »»».
FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV
LUGANO, Switzerland and WOODCLIFF LAKE, New Jersey, January 12, 2011 – Helsinn Group and Eisai Inc. announced today that the U.S.
Food and Drug Administration (FDA) has agreed to the safety and efficacy
protocols for Phase III trials with an investigational oral fixed-dose
combination of netupitant and palonosetron in the prevention of
chemotherapy-induced nausea and vomiting (CINV).
…. Source : Gaea News Network.
Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197
TOKYO and WOBURN, Massachusetts, January 12, 2011 – Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq:
ARQL) today announced that the first patient has been enrolled in the phase
III trial of ARQ 197, an investigational selective inhibitor of the c-Met
receptor tyrosine kinase, in combination with erlotinib, for patients
diagnosed with non-squamous, non-small cell lung …. Original article : Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197.
St. Andrews Country Club of Boca Raton Members Team With Morgan Pressel to Raise $502,000 to Fight Breast Cancer
BOCA RATON, Florida, January 12, 2011 – The Kathryn Krickstein Pressel MammoVan
(www.lpga.com/content_1.aspx?pid=26137&mid=2) purchased in 2009
through fundraising efforts of St. Andrews Country Club members tested more
than 1,000 women in Palm Beach County, 875 of whom had never had a mammogram.
With much of the funds raised this year, the Kathryn Krickstein Pressel
MammoVan continues providing affordable and …. Original source : St. Andrews Country Club of Boca Raton Members Team With Morgan Pressel to Raise $502,000 to Fight Breast Cancer.
European eHealth Week 2011: Registration Opens; Strong Support From Leading Hospitals and Associations
Key Stakeholders Make Decisive Leap Towards Europe's Largest eHealth Event (Budapest, Hungary, 10-12 May, 2011)
BRUSSELS and BUDAPEST, Hungary, January 13, 2011 – Registration is now open for the eHealth event of the year, eHealth Week
2011, which takes place in Budapest, Hungary on 10-12 May, 2011
(www.ehealthweek.org). The Hungarian Presidency of the Council of the
European Union, … Read the original article on Gaea Times at : European eHealth Week 2011: Registration Opens; Strong Support From Leading Hospitals and Associations.
Apollo Munich Health Insurance Wins Celent Model Insurer Asia 2011 Award
Winner in 'Policy Administration System' Category for Mastek's ElixirAsia Health Solution
MUMBAI, India, January 13, 2011 – Apollo Munich Health Insurance Co. Ltd. (AMHI), was
felicitated with the Celent Model Insurer Asia 2011 award in the Policy
Administration System (PAS) category. The award recognizes excellence in
technology best practices at insurers in Asia, in various categories.
[..] Read the original article: here.
Biosense Webster Successfully Completes First Clinical Atrial Fibrillation Ablation Cases in the European Union Using the THERMOCOOL(R) SMARTTOUCH(TM) Contact Force Sensing Catheter
THERMOCOOL(R) SMARTTOUCH(TM) Catheter from Biosense Webster Enables Contact Force Sensing in the Ablation of Atrial Fibrillation
WATERLOO, Belgium, January 13, 2011 – Biosense Webster, Inc., a Johnson & Johnson company, and a worldwide
leader in the diagnosis and treatment of cardiac arrhythmias, announced the
successful completion of the first clinical cases with the new THERMOCOOL(R)
SMARTTOUCH(TM) Contact Force … Original source on Gaea Times at : Biosense Webster Successfully Completes First Clinical Atrial Fibrillation Ablation Cases in the European Union Using the THERMOCOOL(R) SMARTTOUCH(TM) Contact Force Sensing Catheter.
Eisai Opens for Business in the Netherlands
Epilepsy Treatment Zonegran(R) First Commercially Available Product
HATFIELD, England, January 13, 2011 – Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters:
Tokyo; President and CEO: Haruo Naito) announces the establishment of its
sales and marketing operation in its wholly owned subsidiary in the
Netherlands based in Amsterdam. The first Eisai product on the Dutch market
is the … Read : Eisai Opens for Business in the Netherlands.